Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04463160

Study of the Factors Favoring the Transition From Prediabetes to Diabetes on Reunion Island.

The management of diabetes and its complications in Reunion island is one of the priority areas of health. Indeed, the impact of diabetes on the health of the Reunion island population is major: the prevalence of diabetes treated in Reunion island is the highest in France (10% of the population), and gestational diabetes is found in 10% of pregnancies. Reunionese diabetics develop severe complications, in particular cardiovascular (strokes, myocardial infarction).

This results in 3 times higher mortality linked to diabetes on Reunion Island, in particular among those under 65 years of age. Despite all the screening and prevention programs put in place, the weight of diabetic disease continues to increase in our island, and this is more accelerated than in the other French departments with 4,300 new cases of diabetes / year, 95% of which type 2 diabetics (T2D). The presentation of type 2 diabetic patients in Reunion island also differs from the Metropolis with subjects more often female (56%), thinner and younger at the discovery of diabetes. These data highlight the need to better understand the factors underlying the diabetes "epidemic" in Reunion island.

The rise in blood sugar until the onset of diabetes is a continuous phenomenon reflecting the progressive suffering of the organs used to maintain carbohydrate homeostasis. Thus, we talk about fasting hyperglycemia when the fasting blood sugar is between 1.10 and 1.25 g / L (6.1-6.9 mmol / l) and glucose intolerance when the blood sugar 2 hours after taking 75 g of glucose is between 1.40 and 1.99 g / L (7.8-11.0 mmol / l). Subjects with fasting hyperglycemia or glucose intolerance constitute the target population at very high risk of developing diabetes (up to 70% of these subjects). They have an increased risk of developing diabetes at 1 year multiplied by 5 to 10 compared to normoglycemic subjects, hence the name "prediabetic subjects". This great variability in the risk of developing diabetes highlights the presence of associated risk / protective factors which it is important to find in order to adapt the monitoring and management. It is important in Reunion island, in view of the specificities presented by our population, to understand the pre-diabetes / diabetes transition and the risk and protective factors.

Recruiting

Interested in participating?

Request Info

Key information

Age range

25 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Universitaire de la Réunion

Saint-Pierre, 97448, France

Location status: Recruiting

Location contact

Estelle NOBECOURT, PH

PRINCIPAL_INVESTIGATOR

Samir MEDJANE

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject aged 25 to 70 with pre-diabetes defined by fasting blood sugar between 1.10 and 1.25 g / l (6.1 and 6.9 mmol / l) or blood sugar between 1.40 and 1.99 g / l (7.8 and 11.0 mmol / l) 2 hours after taking 75g of glucose (HGPO test), dating from less than 3 months.
  • Consulting one of the general practitioners involved in the study, whatever the initial reason for the consultation
  • able to answer a telephone survey questionnaire
  • who have never been diagnosed or treated for diabetes with the exception of gestational diabetes
  • Person affiliated or beneficiary of a social security scheme.
  • Free, informed and written consent signed

Exclusion criteria

  • People likely to leave Reunion within 2 years
  • Persons placed under guardianship, curators, safeguard of justice, person participating in another research including an exclusion period still in progress.
  • Person with severely impaired physical and / or psychological health, who, according to the investigator, may affect the compliance of the study participant.
  • Pregnancy in progress

Treatment and study plan

prevention program for prediabetes "Say No to Diabetes"

Other

10 therapeutic education sessions

Primary outcomes

  1. The impact of the "Say No to Diabetes" intervention on the incidence of type 2 diabetes

    Time frame: 2 years

    Diabetes : fasting blood glucose ≥ 1.26 g / l (7 mmol / l), or blood sugar 2 hours after taking 75 g of glucose during HGPO ≥2 g / l (11.1 mmol / l)

Secondary outcomes

  1. Numer of patients with diagnosic of type 2 diabetes in subjects identified as pre-diabetic

    Time frame: 2 years

    Prediabetes : fasting blood sugar is between 1.10 and 1.25 g / l (6.1 and 6.9 mmol / l) or a blood sugar level is between 1.40 and 1.99 g / l (7.8 and 11 0.0 mmol / l) 2 hours after taking 75g of glucose (HGPO test) Diabetes : fasting blood glucose ≥ 1.26 g / l (7 mmol / l), or blood sugar 2 hours after taking 75 g of glucose during HGPO ≥2 g / l (11.1 mmol / l)

  2. Number of patients return to normal blood sugar

    Time frame: 2 years

    Normal blood sugar : fasting blood glucose <1.10 g / l (6.1mmol / l), or blood sugar 2 hours after taking 75 g of glucose during HGPO <1.40g / l (7.8 mmol / l).

  3. HbA1c assay for the diagnosis of glucose intolerance and prediabetes compared to HGPO

    Time frame: 2 years

    HbA1c assay

Study contacts

Contact information is provided by the study sponsor or research team.

Samir MEDJANE

CONTACT

[email protected]

0262359750 ext. +262

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Réunion

Other

Registry information

Official study title

Study of the Factors Favoring the Transition From Prediabetes to Diabetes on Reunion Island. Impact of the "Say No to Diabetes" Intervention.

Acronym: PREDIABRUN

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Jul 9, 2020
Registry last updated
Jul 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.